Is a cure for Parkinson's disease hiding inside us?

Jaime Santos, Irantzu Pallarès*, Salvador Ventura

*Corresponding author for this work

Research output: Contribution to journalArticleResearchpeer-review


α-Synuclein (a-syn) oligomers and fibrils are behind neurodegeneration in Parkinson's disease (PD), but therapeutically targeting them is challenging. Amphipathic and cationic helical peptides inhibit amyloid formation and suppress neurotoxicity by selectively binding the solvent-accessible regions in these toxic species. Can endogenous peptides, like LL-37, constitute a new therapeutic paradigm in PD?

Original languageEnglish
JournalTrends in Biochemical Sciences
Publication statusPublished - 1 Feb 2022


  • amyloid fibril
  • disease-modifying therapy
  • LL-37
  • oligomer
  • Parkinson's disease
  • α-synuclein


Dive into the research topics of 'Is a cure for Parkinson's disease hiding inside us?'. Together they form a unique fingerprint.

Cite this